FI66120C - Foerfarande foer stabilisering av 4-metyl-5-(2'-kloretyl)-tiazol - Google Patents
Foerfarande foer stabilisering av 4-metyl-5-(2'-kloretyl)-tiazol Download PDFInfo
- Publication number
- FI66120C FI66120C FI791324A FI791324A FI66120C FI 66120 C FI66120 C FI 66120C FI 791324 A FI791324 A FI 791324A FI 791324 A FI791324 A FI 791324A FI 66120 C FI66120 C FI 66120C
- Authority
- FI
- Finland
- Prior art keywords
- mixture
- cmt
- base
- carrier
- fatty acids
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 150000004665 fatty acids Chemical class 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 8
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 7
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000011261 inert gas Substances 0.000 claims description 6
- 239000012299 nitrogen atmosphere Substances 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims description 5
- 229910001385 heavy metal Inorganic materials 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 239000011630 iodine Substances 0.000 claims description 5
- 239000012298 atmosphere Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims 1
- 239000002585 base Substances 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 16
- 238000000354 decomposition reaction Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000007017 scission Effects 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 239000007903 gelatin capsule Substances 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000003925 fat Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000010775 animal oil Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940093633 tricaprin Drugs 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical class CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical class [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052743 krypton Inorganic materials 0.000 description 1
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229940093609 tricaprylin Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Lubricants (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT296178 | 1978-04-25 | ||
| AT296178A AT358530B (de) | 1978-04-25 | 1978-04-25 | Stabilisierungsverfahren |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI791324A FI791324A (fi) | 1979-10-26 |
| FI66120B FI66120B (fi) | 1984-05-31 |
| FI66120C true FI66120C (fi) | 1984-09-10 |
Family
ID=3543124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI791324A FI66120C (fi) | 1978-04-25 | 1979-04-24 | Foerfarande foer stabilisering av 4-metyl-5-(2'-kloretyl)-tiazol |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4247702A (ru) |
| EP (1) | EP0005121B1 (ru) |
| JP (1) | JPS54147914A (ru) |
| AT (1) | AT358530B (ru) |
| AU (1) | AU523518B2 (ru) |
| CA (1) | CA1113941A (ru) |
| CS (1) | CS208779B2 (ru) |
| DD (1) | DD142962A5 (ru) |
| DE (2) | DE2963835D1 (ru) |
| DK (1) | DK155978C (ru) |
| ES (1) | ES480590A1 (ru) |
| FI (1) | FI66120C (ru) |
| GR (1) | GR66987B (ru) |
| HU (1) | HU179741B (ru) |
| IE (1) | IE48778B1 (ru) |
| IL (1) | IL57292A (ru) |
| NO (1) | NO150317C (ru) |
| NZ (1) | NZ190240A (ru) |
| PT (1) | PT69532A (ru) |
| SU (1) | SU959626A3 (ru) |
| UA (1) | UA5545A1 (ru) |
| YU (1) | YU42302B (ru) |
| ZA (1) | ZA791661B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58159425A (ja) * | 1982-03-18 | 1983-09-21 | Fujisawa Pharmaceut Co Ltd | ゲル基剤 |
| SE9303281D0 (sv) * | 1993-10-07 | 1993-10-07 | Astra Ab | New formulation |
| NZ518020A (en) | 1999-10-15 | 2004-02-27 | Sucampo Ag | Novel composition and method for stabilizing the same |
| US9884024B2 (en) * | 2005-12-27 | 2018-02-06 | Hemant N Joshi | Physically dispersed, molecularly dissolved and/or chemically bound drug(s) in an empty, hard capsule shell composition |
| JP2013032289A (ja) * | 2009-10-28 | 2013-02-14 | Daiichi Sankyo Co Ltd | ワックス安定製剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2844512A (en) * | 1954-11-05 | 1958-07-22 | Upjohn Co | Fumagillin enveloped in fatty or waxy substance and enclosed in ultraviolet opaque container |
| US3265629A (en) * | 1958-12-22 | 1966-08-09 | Ncr Co | Coating by phase separation |
| US3146167A (en) * | 1961-10-05 | 1964-08-25 | Smith Kline French Lab | Method of preparing sustained release pellets and products thereof |
| FR1416304A (fr) * | 1961-10-10 | 1965-11-05 | Smith Kline French Lab | Perfectionnements apportés aux tablettes et comprimés renfermant une importante quantité d'ingrédient actif libéré pendant un laps de temps prolongé, et aux procédés pour leur préparation |
| FR1536904A (fr) * | 1962-12-19 | 1968-09-02 | Smith Kline French Lab | Procédé de préparation de pilules pharmaceutiques à libération progressive de leur principe actif |
| SE319577B (ru) * | 1966-03-08 | 1970-01-19 | Astra Ab | |
| JPS4971127A (ru) * | 1972-11-18 | 1974-07-10 | ||
| NL189235C (nl) * | 1974-02-28 | 1993-02-16 | Akzo Nv | Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking. |
| NL7510104A (nl) * | 1975-08-27 | 1977-03-01 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat. |
| US4202888A (en) * | 1976-07-12 | 1980-05-13 | Kali-Chemie Pharma Gmbh. | Readily enterally absorbable pharmaceutical compositions of cardiac glycosides and preparation thereof |
| DE2631281A1 (de) * | 1976-07-12 | 1978-01-19 | Kali Chemie Pharma Gmbh | Verfahren zur erhoehung der loeslichkeit von schwerloeslichen arzneistoffen zum zwecke deren applikation in gelatinekapseln |
-
1978
- 1978-04-25 AT AT296178A patent/AT358530B/de not_active IP Right Cessation
-
1979
- 1979-04-06 ZA ZA791661A patent/ZA791661B/xx unknown
- 1979-04-09 EP EP79810032A patent/EP0005121B1/de not_active Expired
- 1979-04-09 GR GR58840A patent/GR66987B/el unknown
- 1979-04-09 DE DE7979810032T patent/DE2963835D1/de not_active Expired
- 1979-04-10 US US06/028,914 patent/US4247702A/en not_active Expired - Lifetime
- 1979-04-17 YU YU910/79A patent/YU42302B/xx unknown
- 1979-04-20 NZ NZ190240A patent/NZ190240A/xx unknown
- 1979-04-20 CS CS792752A patent/CS208779B2/cs unknown
- 1979-04-23 PT PT69532A patent/PT69532A/pt unknown
- 1979-04-23 AU AU46373/79A patent/AU523518B2/en not_active Expired
- 1979-04-23 NO NO791339A patent/NO150317C/no unknown
- 1979-04-23 CA CA326,080A patent/CA1113941A/en not_active Expired
- 1979-04-24 DK DK167879A patent/DK155978C/da active IP Right Grant
- 1979-04-24 FI FI791324A patent/FI66120C/fi not_active IP Right Cessation
- 1979-04-24 DD DD79212450A patent/DD142962A5/de unknown
- 1979-04-24 JP JP5078179A patent/JPS54147914A/ja active Granted
- 1979-04-24 DE DE2916573A patent/DE2916573C2/de not_active Expired
- 1979-04-25 SU SU792757925A patent/SU959626A3/ru active
- 1979-04-25 HU HU79PA1351A patent/HU179741B/hu unknown
- 1979-04-25 UA UA2757925A patent/UA5545A1/uk unknown
- 1979-04-25 ES ES480590A patent/ES480590A1/es not_active Expired
- 1979-05-15 IL IL57292A patent/IL57292A/xx unknown
- 1979-08-08 IE IE836/79A patent/IE48778B1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4954714B2 (ja) | 脂肪毒性の改善剤 | |
| CA2150576C (fr) | Compositions injectables a base de derives des taxanes | |
| EP0593601B1 (fr) | Nouvelles compositions a base de derives de la classe des taxanes | |
| FR2553662A1 (fr) | Composition d'acides gras combines, pour reduire les taux de triglycerides et de cholesterol du sang | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FI66120B (fi) | Foerfarande foer stabilisering av 4-metyl-5-(2'-kloretyl)-tiazol | |
| FR2541287A1 (fr) | Preparation stable administrable par voie orale de macrolides antibiotiques et procede pour les stabiliser | |
| FR2524314A1 (fr) | Medicament a action salidiuretique, contenant des dihydropyridines | |
| JPH0761954B2 (ja) | コレステロール低下または上昇抑制剤 | |
| EP1147167A1 (fr) | Procede d'obtention d'une huile enrichie en acides gras hydroxyoctadecadienoiques (hode) ou de ses esters, a partir d'un melange huileux contenant de l'acide linoleique, ou ses esters | |
| JPH01153629A (ja) | 制癌剤 | |
| JPH04288016A (ja) | 活性型ビタミンｄ３類軟カプセル剤の製造方法 | |
| EP0113330B1 (fr) | Composés énamides acylés, compositions pharmaceutiques les contenant, utilisation de ces composés et procédé de préparation de ces composés | |
| EP1555894A2 (fr) | Nouvelle compositions neutraceutiques et pharmaceutiques et leurs utilisations | |
| WO2004073698A1 (fr) | Utilisation therapeutique de glycerols acyles et de leurs analogues azotes et sulfures | |
| WO1995021624A1 (fr) | Preparation sous forme de solution a base d'une forte concentration d'aureobasidine | |
| BE738239A (ru) | ||
| CH685700A5 (fr) | Esters nitriques de 1,2-benzo-isothiazolyl-3(2H)one-1,1-dioxyde, procédé de préparation de ces esters et médicaments contenant ces esters. | |
| BE678902A (ru) | ||
| JPH07267875A (ja) | オーレオバシジン類の高濃度溶液製剤 | |
| JPS58210010A (ja) | 抗腫瘍剤 | |
| BE894696A (fr) | Nouveaux medicaments a base de 9,10-dihydro-ergonine pour le traitement de l'arteriosclerose | |
| BE825194A (fr) | Hydrazide de n-benzene-sulfonyl-beta-alanine comme agent immunosupressif sur et actif | |
| BE626589A (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired | ||
| MA | Patent expired |
Owner name: AB ASTRA |